Abstract
Background
Pneumocystis carinii pneumonia (PCP) is a rare form of pneumonia associated with immune-suppression. It is common in patients with AIDS and with a CD4 count of less than 200 cells/mm3. We report a case of PCP secondary to immune-suppression in a 41-year-old man with psoriatic arthritis being treated with the immune-modulatory agent etanercept.
Methods
Diagnosis of PCP was made histologically using tissue obtained via transbronchial biopsy.
Results
There was a good response to standard treatment with high-dose co-trimoxazole.
Conclusion
This report highlights a recognised but previously unreported complication of etanercept.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
The National Institute of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia (1990) Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 323:1500–1504
Pareja JG, Garland R, Koziel H (1998) Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 113:1215–1224
Bakleh M, Tleyjeh I, Matteson EL, Osmon DR, Berbari EF (2005) Infectious complications of tumor necrosis factor-α antagonists. Int J Dermatol 44(6):443–448
Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259
Olsen NJ, Stein CM (2004) New drugs for rheumatoid arthritis. N Engl J Med 350:2167–2179
Oien KA, Black A, Hunter JA, Madhok R (1995) Pneumocystis carinii pneumonia in a patient with rheumatoid arthritis, not on immunosuppressive therapy and in the absence of human immunodeficiency virus infection. Br J Rheumatol 34:677–679
Mori S, Imamura F, Kiyofuji C et al (2006) Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumour necrosis factor alpha neutralizing antibody. Mod Rheumatol 16(1):58–62
Gruden JF, Huang L, Turner J et al (1997) High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol 169:967–975
Shelhamer JH, Gill VJ, Quinn TC et al (1996) The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med 124:585–599
Saito K, Nakayamada S, Nakano K et al (2004) Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases. Rheumatology (Oxford) 43:479–485
Navin R (2001) Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of Pneumocystis carinii pneumonia in patients with HIV-1: a prospective study. Lancet 358:545–549
Krebs S, Gibbons RB (1996) Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia. Mil Med 161(1):58–60
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lahiff, C., Khiaron, O.B., Nolan, N. et al. Pneumocystis carinii pneumonia in a patient on etanercept for psoriatic arthritis. Ir J Med Sci 176, 309–311 (2007). https://doi.org/10.1007/s11845-007-0087-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-007-0087-x